THE US National Cancer Institute plans to test nationwide a drug called taihoxifen that might prevent breast cancer, lower the number of deaths from heart attacks and reduce the number of broken bones among middle-aged and older women. The trial, over a period of five years, will involve about 16,000 women between the ages of 35 and 59, half of who will be given a 20-milligram dose of the drug and the others a placebo.
Tamoxifen has some side effects such as blood clotting and early opause, and uterine cancer in older women. The rug has also been linked to liver cancer in rats.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.